Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.46 USD | +10.61% | +7.35% | +158.41% |
Financials (USD)
Sales 2024 * | 72.54M | Sales 2025 * | 68.35M | Capitalization | 242M |
---|---|---|---|---|---|
Net income 2024 * | -168M | Net income 2025 * | -167M | EV / Sales 2024 * | 1.76 x |
Net cash position 2024 * | 115M | Net cash position 2025 * | 281M | EV / Sales 2025 * | -0.57 x |
P/E ratio 2024 * |
-1.56
x | P/E ratio 2025 * |
-1.97
x | Employees | 137 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.18% |
Latest transcript on Nektar Therapeutics
1 day | +10.61% | ||
1 week | +2.82% | ||
Current month | +56.28% | ||
1 month | +61.49% | ||
3 months | +160.71% | ||
6 months | +218.78% | ||
Current year | +158.41% |
Managers | Title | Age | Since |
---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 71 | 06-12-31 |
Robert Chess
CHM | Chairman | 66 | 91-11-30 |
Sandra Gardiner
DFI | Director of Finance/CFO | 58 | 23-04-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
R. Scott Greer
BRD | Director/Board Member | 65 | 09-12-31 |
Roy A. Whitfield
BRD | Director/Board Member | 70 | 00-07-31 |
Robert Chess
CHM | Chairman | 66 | 91-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.32% | 16 M€ | -7.06% | ||
0.06% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 1.46 | +10.61% | 1,607,134 |
24-04-26 | 1.32 | 0.00% | 559,095 |
24-04-25 | 1.32 | -4.35% | 1,054,027 |
24-04-24 | 1.38 | -2.82% | 958,333 |
24-04-23 | 1.42 | +4.41% | 1,101,026 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+158.41% | 242M | |
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- NKTR Stock